COVID vaccine supply deal dispute: JnJ to pay USD 50 million to Emergent

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-07-09 12:19 GMT   |   Update On 2024-07-16 15:35 GMT
Advertisement

Emergent BioSolutions has said that Johnson & Johnson has agreed to settle claims arising from the termination of the manufacturing deal for the latter's COVID-19 vaccine with a payment of USD 50 million.

In 2022 J&J informed Emergent of its decision to terminate the deal, citing breaches including failure to supply COVID-19 vaccine drug substance on the part of the contract manufacturer.
Emergent had said J&J breached the agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.
Advertisement
According to Reuters, under the five-year agreement , signed in 2020, Emergent would provide contract manufacturing services to produce the COVID-19 vaccine drug substance for commercial manufacturing. It was valued at about $480 million for the first two years.
The U.S. health regulator had limited the use of the J&J vaccine in 2022 due to the risk of a rare blood clotting syndrome.



Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News